Compare Amphastar Pharmaceuticals Inc (AMPH) vs Nutanix Inc (NTNX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Nutanix Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Nutanix Inc trades at $54.79 (market cap $14.81B). The key difference: Nutanix Inc is far larger — about 17.9× Amphastar Pharmaceuticals Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | NTNX | |
|---|---|---|
Market Cap | $826.08M | $14.81B |
Sector | Health | Technology |
52-Week High | $30.81 | $81.12 |
52-Week Low | $16.87 | $34.41 |
Enterprise Value | $1.22B | $14.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Nutanix (NTNX) trades at $54.79, down 1.33% on the day, with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals, with Q1 2026 EPS of $0.47 beating expectations and a robust gross profit margin of 87.09%. Recent news highlights momentum, including NVIDIA certification for its storage solution and positive analyst coverage.
The outlook is positive, driven by consistent earnings beats, expanding AI infrastructure opportunities, and a consensus price target of $57.80. Key risks include high valuation multiples and competitive pressures in the hybrid cloud market. Wall Street sentiment is bullish, with 62.5% of analysts rating the stock a Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
